

Consumers have dramatically changed their use of traditional health care services since the outbreak of COVID-19, with many reporting a concern for in-person care and embracing virtual care, according to <u>a new national</u> <u>survey released last month</u> by the Alliance of Community Health Plans (ACHP) and AMCP. The pandemic, however, has not dramatically altered the popularity of in-person pharmacy visits. Nearly half (49 percent) report feeling "very comfortable" picking up prescriptions at their local pharmacy and speaking with their pharmacists about their medications. Since the pandemic started, nearly half (47 percent) received new medication, and the overwhelming majority (90 percent) did so at a local retail pharmacy. This consumer confidence presents an enormous opportunity for pharmacists to support a strained health care system, because the same consumers are delaying visits with other health care providers due to safety concerns. The ACHP/AMCP survey was cited in several national new stories, including <u>Fierce Healthcare</u>.




Read AMCP CEO Susan A. Cantrell's recent blog post, <u>"Shedding Light on</u> <u>Consumer Health Care Attitudes During COVID-19.</u>" Cantrell looks at findings in last month's ACHP/AMCP survey that underscore the role pharmacists can play during the pandemic, including the fact 39 percent of respondents said they would feel comfortable being tested for COVID-19 at a pharmacy. Cantrell also highlights opportunities in telehealth, with 28 percent saying they used some type of virtual care in the past three months, nearly tripling previously documented averages.



AMCP Joins Peers in Promoting Patient Access to Rx Drugs

AMCP joined 14 organizations representing the pharmaceutical supply and payment chain in a letter to the Trump Administration and congressional leaders urging policy principles to promote undisrupted patient access to medications during the COVID-19 pandemic. The policy principles seek to mitigate drug shortages and ensure the safety, security, and reliability of the pharmaceutical supply chain amidst this unprecedented health care system challenge. They include calls for both the private and public sectors to work together to sustain access to care for patients and help to mitigate disruptions and shortages.

Hear about a different treatment option >



Cantrell Participates in PQA Fireside Chat to Describe how Managed Care Pharmacy Is Addressing the Pandemic

AMCP CEO Susan A. Cantrell joined Ceci Connolly, president and CEO of the Alliance of Community Health Plans (ACHP), to discuss the effects of COVID-19 on health care delivery at a May 14 fireside chat, which was part of the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting. Cantrell noted that the sudden and vast



### A once-weekly injection

for patients with hemophilia A expansion in telehealth visits may be one of the most immediate and largest long-term impacts of the pandemic on the health care system. She also explained how managed care pharmacy professionals are working to ensure patients have access to their medications during this pandemic. For example, organizations are instituting processes and waiving certain requirements — including authorizations and fill requirements — to make sure patients can conveniently obtain their medications. Read coverage of the event in Pharmacy Times.

Stay on top of the latest developments impacting managed care pharmacy: access the most up-to-date information in the <u>COVID-19 Resource Center</u>.



Univ. of California, San Francisco School of Pharmacy Wins AMCP Foundation's 20th Annual P&T Competition

Besting nearly 70 schools of pharmacy from across the country, the University of California, San Francisco School of Pharmacy (*pictured*) took top honors in the AMCP Foundation's <u>20th Annual National Student Pharmacy &</u> <u>Therapeutics (P&T) Competition</u>. The University of North Carolina Eshelman School of Pharmacy took second place and Rutgers University Ernest Mario School of Pharmacy came in third place. The competition replicates the process that health care decision makers take in examining a new pharmaceutical product for placement on a formulary. This year's case study simulated a new indication review for add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older. The Foundation is deeply grateful to Genentech, Inc., lead sponsor, as well as Supernus Pharmaceuticals and Sanofi US Services Inc. for their generous support of the competition. The Foundation also thanks FormularyDecisions for hosting AMCP eDossiers.



AMCP Foundation Awards Best Posters for Research on Opioid Use, Migraine Therapy, and Preterm Births

AMCP Foundation presented its <u>2020 Best Poster Awards</u> to three rising pharmacists for their research into opioid utilization, migraine therapy, and preterm births. The 2020 awardees are:

- Best Poster by a Student Pharmacist: Waverly Yang, University of Texas at Austin College of Pharmacy (opioid utilization)
- Best Poster by a Resident or Fellow: Kayla Thompson, PharmD, Pharmacy Resident, Gateway Health Plan (migraine treatment)
- Best Poster by a Graduate Student: Shiyu Zhang, MS, PhD Candidate, University of Texas at Austin College of Pharmacy (preterm birth)

The competition, conducted in partnership with CVS Health, took place during AMCP eLearning Days, April 20-24. Virtual posters were judged on factors including scientific merit, methodology, and visual interpretation of data. <u>View all posters.</u>



We recognize that COVID-19 is impacting the entire world. We understand the effect the crisis is having on the managed care pharmacy community, personally and professionally. We appreciate you being an important part of the managed care and AMCP community. Together, we will get through this.

We continue to plan and look forward to AMCP Nexus 2020 from Oct. 20-23 at MGM in Las Vegas. AMCP is working closely with Las Vegas officials and reviewing the latest guidance from public health authorities and will adjust accordingly, if needed. Today's health care climate spurs innovation. AMCP offers various opportunities to present your insights and outcomes with nearly 2,500 managed care pharmacists and health care professionals who are expected to attend Nexus 2020:

<u>Submit research poster abstracts by 11:59pm PT on June 10.</u> The most highly rated abstracts will be selected for a 15-minute podium presentation as part of an education session. Please direct questions about the Nexus 2020 Call for Poster Abstracts to <u>posterabstracts@amcp.org</u>.

Submit a proposal to present an accredited continuing pharmacy education (CPE) session. Sessions must align with one of the Nexus 2020 education tracks: (1) Drugs, Diseases, and the Managed Care Impact; (2) Legislative and Regulatory Trends; (3) Managed Care Research in Action; (4) Specialty Management; and (5) Making the Way for Innovation. Proposals are due by 11:59pm PT on June 15. Read the AMCP Nexus 2020 Call for CPE Session Proposals. For questions, contact education@amcp.org.

<u>Submit a proposal to speak during AMCP Talks</u> on the future trends in health technology and digital therapeutics. Proposals are due by 11:59pm PT on June 15 and must focus on one of the following areas: (1) Using Health Technology to Enhance Managed Care Pharmacy Practice; and (2) Digital Therapeutics: How Can Managed Care Use the Data these Novel Tools Bring? AMCP Talks is non-accredited, and industry is eligible to submit proposals. <u>Read the AMCP Nexus 2020 Call for AMCP Talks</u>. For questions, contact <u>education@amcp.org</u>.

And don't forget to mark your calendar! Registration for Nexus 2020 opens on Tuesday, June 9.



## Sponsor AMCP's Partnership Forum on Rare Diseases

Does your company serve the needs of individuals suffering from rare diseases? If so, we invite your company to sponsor AMCP's Partnership Forum, "Preparing for and Managing Rare Diseases", which will be held virtually from Sep. 8-10 (agenda 2-4 hours/day).

AMCP Partnership Forums convene decision makers in managed and integrated care and life science companies to discuss key issues facing managed care pharmacy and collaboratively help shape the changing health care landscape.

The forum on rare diseases will focus on the role of managed care organizations, life science companies, prescribers, patients, employers, and the government in supporting access to million-dollar, breakthrough therapies as well as identifying and managing these small but important patient populations in a changing health care system post COVID-19.

Forums are invitation-only and are supported by sponsorship. Forum findings are shared with managed care professionals via webinars and proceedings published in the *Journal of Managed Care & Specialty Pharmacy*. Sponsors can also work with AMCP to share forum findings with the FDA and policymakers.

Join the conversation to identify key actions that can support timely access to and the appropriate management of treatments for rare diseases. **Email <u>corpopportunities@amcp.org</u> to become a corporate sponsor.** 



New AMCP Resource Focuses on Atherosclerotic Cardiovascular Disease

AMCP has launched a <u>new web resource</u> on atherosclerotic cardiovascular disease (ASCVD), which is defined as acute coronary syndromes, a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin. The resource includes info graphics and information on using icosapent ethyl for risk reduction and articles on ASCVD from the *Journal of Managed Care & Specialty Pharmacy*. AMCP is pleased to work with Medtelligence and Amarin to offer these resources to you, with a specific focus on the use of icosapent ethyl as a treatment for risk reduction.



## Sessions from AMCP eLearning Days Are Available Online

Recordings of all 10 sessions from AMCP eLearning Days, April 20-24, are <u>available online</u>. AMCP members can access the recordings for free, and non-members can access them for \$30 each. Select recordings offer continued pharmacy education (CPE) credit. Sessions include:

- 2019-2020 Pharmaceutical Marketplace Trends
- <u>Cannabis Use in Health Care: What Payers Need to Know Home Study</u>
- Digital Therapeutics: Understanding the Emerging Product Class Home Study
- Getting Up to Speed on Prescription Drug Pricing Reform Efforts Home Study



Continuing Education: Optimal Integration of PARP Inhibitors Into the Management of Ovarian Cancer

Join a free continuing educational program that reviews evidence pertaining to the use of PARP-inhibitors in treating epithelial ovarian cancer (OC). This cancer type comprises 90 percent of all malignant ovarian neoplasms and is the fifth most common cause of cancer mortality in American women. Although between 80 percent and 90 percent of patients respond to chemotherapy (platinum-sensitive disease), recurrence is virtually universal. PARP inhibitors are demonstrating significant progression-free survival and quality of life improvements for many of these patients. The video discussion will differentiate between the available PARP inhibitors and examine the managed care considerations for these medications. This educational activity is supported by an unrestricted educational grant from Tesaro Inc. Learn more and access the program.



PIE Webinar: Obeticholic acid: An Investigational Drug for the Treatment of Liver Fibrosis due to NASH AMCP will host a pre-approval information exchange (PIE) webinar sponsored, developed, and presented by Intercept Pharmaceuticals Inc. on Thursday, June 4 at 2pm ET. Obeticholic acid is not FDA-approved for use in the preventive treatment of Liver Fibrosis due to Nonalcoholic Steatohepatitis (NASH). This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. Register here.



# PIE Webinar: The Potential Role of Biomarkers in Alzheimer's Disease

AMCP will host a pre-approval information exchange (PIE) webinar sponsored, developed, and presented by Biogen on Tuesday, June 23, 2020, from 2:00 pm to 3:00 pm ET. Alzheimer's disease is a significant healthcare concern due to the growth of the aging population and the rising burden of direct and indirect costs. Changing this trajectory begins with an understanding of the disease at its earliest stages. This session will explore the potential role of biomarkers in Alzheimer's disease, including pathophysiology, implications in the disease continuum, and diagnostic methods for early detection. This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. <u>Register here</u>.

#### Log in virtually for up to date pre-approval information

START TODAY

### Preapproval Information at Your Fingertips with FormularyDecisions

FormularyDecisions

Does your planning process require access to product information earlier and earlier in the development cycle? FormularyDecisions (FD) provides payers and other health care decision-makers with a centralized, virtual platform to easily facilitate this critical preapproval information exchange (PIE). Available materials include product pages, manufacturer curated information via the manufacturer resource center, pipeline summary information via the P&T Prep Kit Snapshots, and newly available AMCP PIE webinars for more interactive product education. For insights on PIE best practices, access the AMCP webinar recording hosted on June 2, 2020 with the FD team entitled, "Out in Front – Effective Pre-approval Communications with Payers." Payers who are not current users of FD can register for free at FormularyDecisons.com, or manufacturers can contact info@formularydecisions.com for subscription options.

#### AMCP

675 North Washington Street, Suite 220, Alexandria, VA 22314 703 684 2600 I <u>www.amcp.org</u>



Editor Neal Learner, Press Officer & Content Editor

For inquiries or submissions, please contact <u>nlearner@amcp.org</u>.

Manage My Emails